US OptionsDetailed Quotes
HRTX240816P3000
- 0.18
- +0.03+20.00%
15min DelayClose Jul 22 16:00 ET
0.18High0.18Low
0.18Open0.15Pre Close1 Volume790 Open Interest3.00Strike Price18.00Turnover115.26%IV11.88%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type-0.3537Delta0.3861Gamma11.64Leverage Ratio-0.0071Theta-0.0009Rho-4.12Eff Leverage0.0031Vega
Heron Therapeutics Stock Discussion
MT Newswires· 2 mins ago
Heron Therapeutics (HRTX) said Monday that its drug Zynrelef is included as a non-opioid pain medicine in proposed 2025 Medicare programs.
Zynrelef will be included under Medicare's Outpatient Prospective Payment System and the Medicare Ambulatory Surgical Center, beginning April 1.
The company said Zynrelef was qualified because it is appro...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics announced the submission of a Prior Approval Supplement (PAS) to the FDA for the ZYNRELEF Vial Access Needle (VAN). The VAN aims to replace the current vented vial spike (VVS) in ZYNRELEF kits, reducing preparation time significantly from up to 3 minutes to 20-45 seconds. The VAN's user-friendly design is expected to simplify a...
$Heron Therapeutics(HRTX.US)$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US)$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US)$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US)$ & $Regeneron Pharmaceuticals(REGN.US)$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
No comment yet